B of A Securities Maintains Buy on Immunovant, Raises Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Gerberry maintains a Buy rating on Immunovant (NASDAQ:IMVT) and raises the price target from $26 to $28.
May 23, 2023 | 2:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B of A Securities maintains a Buy rating on Immunovant and raises the price target from $26 to $28.
The news of B of A Securities maintaining a Buy rating and raising the price target for Immunovant is positive for the company's stock. This indicates that the analyst has confidence in the company's performance and growth potential, which could lead to an increase in demand for the stock and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100